Skip to content
Monday 10 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,862.50
-0.35%
DAX
26,323.88
+0.02%
CAC 40
8,726.03
+0.13%
STOXX 50
6,535.62
+0.18%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Friday 04 December 2020 6:01 am  |  Updated:  Friday 04 December 2020 12:22 pm

Pfizer vaccine ‘arrives in UK’ for distribution

By: Poppy Wood

Add as a preferred source on Google

The Pfizer/Biontech coronavirus vaccine has arrived in the UK ready for distribution to the public, marking a major step in the global fight against the pandemic.

Freight deliveries from Belgium have hit UK shores and will now transport the vaccine at -70C across the devolved nations.

The UK on Wednesday became the first country in the world to give the green light for the Pfizer vaccine, and has ordered 40m doses — enough to vaccinate 20m people.

An initial shipment of 800,000 doses has passed UK “batch testing”, and will be send out to vaccinate the most vulnerable members of the population from next week.

Prime Minister Boris Johnson said the NHS is preparing for rollout of the vaccine across 50 hospital hubs from next week.

However, he urged cautious optimism over the timeline of the vaccine rollout, warning that it would come with “immense logistical challenges”.

Sir Simon Stevens, chief executive of NHS England, told a Downing Street press briefing yesterday that the temperature requirements of the jab would present significant transit limitations.

The Medicines and Healthcare products Regulatory Agency (MHRA) has so far refused to grant approval for the vaccine containers, each holding 975 doses, to be split up.

Read more

Verdiva Bio Appoints Cardiometabolic Leader Steve Marso as Chief Medical Officer

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Coronavirus
  • Vaccine

Trending Articles

  • Nottingham Forest owner Marinakis sues Crystal Palace for defamation

  • Back to basics: Sainsbury’s gradual retreat from the British high street

  • Thames Water faces fresh threat to survival after pensions regulation breach

  • Hargreaves Lansdown orders staff back to office

  • As it happened: Intel, Arm shares slide; Oil climbs higher

More from Morning Wire

  • Verdiva Bio Appoints Cardiometabolic Leader Steve Marso as Chief Medical Officer

    Business Wire
  • Rehlko Announces €12 Million Expansion of Power Control & Distribution Manufacturing Facility in Cholet, France

    Business Wire
  • SS&C Expands Tokenized Investment Capabilities with Digital Cash Settlement

    Business Wire
  • Osmose Europe Ltd. Strengthens and Expands Electric Utility Infrastructure Solutions with the Acquisition of MP Power Ltd.

    Business Wire
  • First Trust Global Portfolios Management Limited Announces Distribution for certain sub-funds of First Trust Global Funds ICAV

    Business Wire
  • Targa Newfoundland Unveils Full Sponsor Ecosystem, Announces Lives Showcase at IBC 2026 Amsterdam

    Business Wire
  • Northern Trust Appointed to Support Invesco’s New Index-Tracking Mutual Fund Range

    Business Wire
  • Lehman Brothers Treasury Considers Sale and Final Wind-Down

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook